153 related articles for article (PubMed ID: 21172078)
1. Designing adjuvant treatment based on biological measurements in the neoadjuvant setting.
Smith IE; Kotsori A
Breast Cancer Res; 2010 Dec; 12 Suppl 4(Suppl 4):S16. PubMed ID: 21172078
[No Abstract] [Full Text] [Related]
2. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Model for Testing Emerging Targeted Therapies in Breast Cancer.
Esposito A; Criscitiello C; Curigliano G
J Natl Cancer Inst Monogr; 2015 May; 2015(51):51-5. PubMed ID: 26063887
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
[TBL] [Abstract][Full Text] [Related]
5. [Role of induction chemo- and radiotherapy in the treatment of locally advance breast cancer].
Voznyĭ EK; Kharchenko VP; Pan'shin GA; Gurov SN; Dobrovol'skaia NI; Galil-Ogly GA; Khmelevskiĭ EV; Alipchenko LA; Bol'shakova SA
Vopr Onkol; 2000; 46(6):736-40. PubMed ID: 11219950
[TBL] [Abstract][Full Text] [Related]
6. Is docetaxel now an essential component of neoadjuvant breast chemotherapy?
Shahab N; Haider S
J Clin Oncol; 2004 May; 22(9):1766; author reply 1766-7. PubMed ID: 15118007
[No Abstract] [Full Text] [Related]
7. Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer.
Ahluwalia MS; Daw HA
J Clin Oncol; 2005 Oct; 23(30):7759-60; author reply 7760-1. PubMed ID: 16234551
[No Abstract] [Full Text] [Related]
8. Analysis of Adjuvant Chemotherapy on Pathological Remission of Breast Cancer.
Jiang B; Liu Q; Gai J; Guan J; Li Q
Comput Math Methods Med; 2021; 2021():5440154. PubMed ID: 34819989
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and prognosis of neoadjuvant chemotherapy is correlated with breast cancer molecular classification.
Dai XL; Han ZB; Yang YT; Qiu J; Liu YF; Feng YZ
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):517-22. PubMed ID: 25907177
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer].
Wang B; Fu JF; Hong ZW
Ai Zheng; 2009 Mar; 28(3):292-6. PubMed ID: 19619445
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response.
Fisher CS; Ma CX; Gillanders WE; Aft RL; Eberlein TJ; Gao F; Margenthaler JA
Ann Surg Oncol; 2012 Jan; 19(1):253-8. PubMed ID: 21725686
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.
Bertucci F; Fekih M; Autret A; Petit T; Dalenc F; Levy C; Romieu G; Bonneterre J; Ferrero JM; Kerbrat P; Soulie P; Mouret-Reynier MA; Bachelot T; Lerebours F; Eymard JC; Deblock M; Lortholary A; Hardy-Bessard AC; Barthelemy P; Bonnefoi H; Charafe-Jauffret E; Bidard FC; Viens P; Lemonnier J; Pierga JY
Lancet Oncol; 2016 May; 17(5):600-11. PubMed ID: 27032301
[TBL] [Abstract][Full Text] [Related]
13. Lessons from the neoadjuvant setting on how best to choose adjuvant therapies.
von Minckwitz G; Loibl S; Maisch A; Untch M
Breast; 2011 Oct; 20 Suppl 3():S142-5. PubMed ID: 22015282
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Chemotherapy: What Are the Benefits for the Patient and for the Investigator?
Hayes DF; Schott AF
J Natl Cancer Inst Monogr; 2015 May; 2015(51):36-9. PubMed ID: 26063884
[TBL] [Abstract][Full Text] [Related]
16. Translating neoadjuvant therapy into survival benefits: one size does not fit all.
De Mattos-Arruda L; Shen R; Reis-Filho JS; Cortés J
Nat Rev Clin Oncol; 2016 Sep; 13(9):566-79. PubMed ID: 27000962
[TBL] [Abstract][Full Text] [Related]
17. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy.
Hoff PM; Valero V; Buzdar AU; Singletary SE; Theriault RL; Booser D; Asmar L; Frye D; McNeese MD; Hortobagyi GN
Cancer; 2000 May; 88(9):2054-60. PubMed ID: 10813717
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
19. Analysis of neoadjuvant therapies in breast cancer with respect to pathological complete response, disease-free survival and overall survival: 15 years follow-up data from Kuwait.
Krishnan Y; Al Awadi S; Sreedharan PS; Sujith Nair S; Thuruthel S
Asia Pac J Clin Oncol; 2016 Mar; 12(1):e30-7. PubMed ID: 23937427
[TBL] [Abstract][Full Text] [Related]
20. [Place of anatomopathology in evaluation of response to neoadjuvant chemotherapy. Prognostic and predictive markers: example of breast cancer].
Abrial C; Bouchet-Mishellany F; Raoelfils I; Cayre A; Curé H; Chollet P; Penault-Llorca F
Bull Cancer; 2006 Jul; 93(7):663-8. PubMed ID: 16873074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
